Additionally, it was shown that osteopontin (OPN), an oncogene involved in tumor progression, is a direct target of ERRα and thus, silencing of ERRα resulted in a marked reduction of OPN at both protein and RNA levels in HT-29 cells, suggesting the significance of targeting ERRα in CRC [96]. The gene discussed is ESRRA; the disease is neoplasm.